

Bruno Mdc Godinho

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11027348/publications.pdf>

Version: 2024-02-01

17
papers

962
citations

623734

14
h-index

940533

16
g-index

18
all docs

18
docs citations

18
times ranked

1473
citing authors

#	ARTICLE	IF	CITATIONS
1	Exosome-mediated Delivery of Hydrophobically Modified siRNA for Huntingtin mRNA Silencing. <i>Molecular Therapy</i> , 2016, 24, 1836-1847.	8.2	351
2	5 [′] ,-Vinylphosphonate improves tissue accumulation and efficacy of conjugated siRNAs in vivo. <i>Nucleic Acids Research</i> , 2017, 45, 7581-7592.	14.5	83
3	Docosahexaenoic Acid Conjugation Enhances Distribution and Safety of siRNA upon Local Administration in Mouse Brain. <i>Molecular Therapy - Nucleic Acids</i> , 2016, 5, e344.	5.1	67
4	Serum Deprivation of Mesenchymal Stem Cells Improves Exosome Activity and Alters Lipid and Protein Composition. <i>IScience</i> , 2019, 16, 230-241.	4.1	61
5	Synthesis and characterization of rabies virus glycoprotein-tagged amphiphilic cyclodextrins for siRNA delivery in human glioblastoma cells: In vitro analysis. <i>European Journal of Pharmaceutical Sciences</i> , 2015, 71, 80-92.	4.0	57
6	Non-Viral Nanosystems for Gene and Small Interfering RNA Delivery to the Central Nervous System: Formulating the Solution. <i>Journal of Pharmaceutical Sciences</i> , 2013, 102, 3469-3484.	3.3	46
7	PEGylated cyclodextrins as novel siRNA nanosystems: Correlations between polyethylene glycol length and nanoparticle stability. <i>International Journal of Pharmaceutics</i> , 2014, 473, 105-112.	5.2	45
8	Delivering a disease-modifying treatment for Huntington's disease. <i>Drug Discovery Today</i> , 2015, 20, 50-64.	6.4	39
9	A High-Throughput Method for Direct Detection of Therapeutic Oligonucleotide-Induced Gene Silencing <i>In Vivo</i> . <i>Nucleic Acid Therapeutics</i> , 2016, 26, 86-92.	3.6	38
10	Pharmacokinetic Profiling of Conjugated Therapeutic Oligonucleotides: A High-Throughput Method Based Upon Serial Blood Microsampling Coupled to Peptide Nucleic Acid Hybridization Assay. <i>Nucleic Acid Therapeutics</i> , 2017, 27, 323-334.	3.6	37
11	Differential nanotoxicological and neuroinflammatory liabilities of non-viral vectors for RNA interference in the central nervous system. <i>Biomaterials</i> , 2014, 35, 489-499.	11.4	36
12	Transvascular Delivery of Hydrophobically Modified siRNAs: Gene Silencing in the Rat Brain upon Disruption of the Blood-Brain Barrier. <i>Molecular Therapy</i> , 2018, 26, 2580-2591.	8.2	36
13	Synthesis and Evaluation of Parenchymal Retention and Efficacy of a Metabolically Stable <i>O</i> -Phosphocholine- <i>N</i> -docosahexaenoyl-serine siRNA Conjugate in Mouse Brain. <i>Bioconjugate Chemistry</i> , 2017, 28, 1758-1766.	3.6	33
14	Cyclodextrins for Non-Viral Gene and siRNA Delivery. <i>Pharmaceutical Nanotechnology</i> , 2012, 1, 6-14.	1.5	16
15	Comparative route of administration studies using therapeutic siRNAs show widespread gene modulation in Dorset sheep. <i>JCI Insight</i> , 2021, 6, .	5.0	9
16	PK-modifying anchors significantly alter clearance kinetics, tissue distribution, and efficacy of therapeutics siRNAs. <i>Molecular Therapy - Nucleic Acids</i> , 2022, 29, 116-132.	5.1	7
17	Disrupting The Brain Keeper To Allow Silencing Of Deleterious Genes In The Nervous System. , 2018, , .		0